Acrivon Therapeutics Q2 GAAP EPS beats estimates

Seeking Alpha··US·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Acrivon Therapeutics reported second-quarter 2026 GAAP EPS of negative $0.43, beating estimates by $0.07. As of June 30, 2026, the company had cash, cash equivalents and investments of $90.0 million, which is expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketIVNews